Development and Characterization of Monoclonal Antibodies Against Nitro-166Tyrosine of High-Density Lipoprotein: Apolipoprotein A1

2018 ◽  
Vol 37 (4) ◽  
pp. 167-174
Author(s):  
Guntur Divya ◽  
N.S. Jayaprakash ◽  
Krishnan Venkataraman
Keyword(s):  
Monoclonal Antibodies ◽  
High Density Lipoprotein ◽  
Density Lipoprotein ◽  
High Density ◽  
Apolipoprotein A1

Production and Characterization of a Reconstituted High Density Lipoprotein for Therapeutic Applications

Vox Sanguinis ◽  
1996 ◽  
Vol 71 (3) ◽  
pp. 155-164 ◽  
Author(s):  
Peter G. Lerch ◽  
Vreni Förtsch ◽  
Gerhard Hodler ◽  
Reinhard Bolli
Keyword(s):  
High Density Lipoprotein ◽  
Density Lipoprotein ◽  
High Density ◽  
Therapeutic Applications

Combined Detection of Free Fatty Acid (FFA) and High-Density Lipoprotein Cholesterol (HDL-C) is a Promising Pretreatment Biomarker for Predicting the Overall Prognosis (OS) of Neuroendocrine Tumours (NETs) in the Colorectum: A Case-Control Study.

2021 ◽  
Author(s):  
Bin Zhu ◽  
Dan Wu ◽  
Yuanyuan Yang ◽  
Pingli Yu ◽  
Haobo Huang ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Free Fatty Acid ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Neuroendocrine Tumours ◽  
Tumour Size ◽  
Density Lipoprotein ◽  
High Density ◽  
Apolipoprotein A1 ◽  
Lipoprotein Cholesterol

Abstract Purpose The aim of the study was to evaluate the prognostic value of free fatty acid (FFA) and high-density lipoprotein cholesterol (HDL-C) in predicting colorectal neuroendocrine tumours (NETs). Methods One hundred patients with pathologically diagnosed colorectal NETs in 2011-2017 were enrolled, and the levels of FFA, HDL-C, low-density lipoproteincholesterol (LDL-C), triglycerides (TGs), cholesterol (CHOL), apolipoprotein A1 (ApoA1) and apolipoprotein B (ApoB) between colorectal NET patients and healthy controls matched by age and sex were compared. In addition, the association of clinicopathological characteristics and follow-up data with FFA and HDL-C was analysed. Results FFA was overexpressed (0.55±0.23 vs. 0.48±0.11, P= 0.006) and HDL-C was underexpressed (1.31±0.41 vs. 1.41±0.29, P=0.046) in colorectal NETs. FFA ≥0.52 mmol/L predicted lymph node metastasis (LNM) (χ2 = 5.964, P=0.015), and HDL-C ≤1.0 mmol/L predicted tumour size ≥2 cm (χ2 = 5.647, P=0.017). No significant association was found between FFA and tumour size (P=0.142) or HDL-C and LNM (P=0.443). FFA ≥0.52 mmol/L (χ2 = 6.016, P=0.014) and HDL-C ≤1.0 mmol/L predicted worse overall survival (OS) (χ2 = 5.488, P=0.019). FFA ≥0.52 mmol/L in combination with HDL-C ≤1.0 mmol/L predicted an even worse prognosis in terms of OS (χ2 = 4.818, P=0.028). Conclusion FFA ≥0.52 mmol/L and HDL-C ≤1.0 mmol/L were promising cut-off values in predicting LNM, tumour size and worse OS in colorectal NETs.

Characterization of a novel high-density lipoprotein antioxidant capacity assay and its application to high-density lipoprotein fractions

2013 ◽  
Vol 46 (9) ◽  
pp. 825-827 ◽  
Author(s):  
Krisztina Gaál ◽  
Hajnalka Lőrincz ◽  
Ildikó Seres ◽  
Mariann Harangi ◽  
Anna V. Oláh ◽  
...  
Keyword(s):  
High Density Lipoprotein ◽  
Antioxidant Capacity ◽  
Density Lipoprotein ◽  
High Density
Sign in / Sign up

Export Citation Format

Share Document